Stanford University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH66974D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

September 2018

Total pages

119

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Stanford University is an educational and research organization that provides graduate and undergraduate programs. The organization's services include education and research facilities. It provides research facilities through its research laboratories and centers. Stanford University includes graduate school of business, school of earth, energy and environmental sciences, graduate school of education, school of engineering, school of humanities and sciences, law school and school of medicine. The organization's academic programs comprise continuing studies, pre-collegiate studies and degrees. It also offers computing and communication infrastructure and support for the teaching, learning and research activities. Stanford University is headquartered in Stanford, California, the US.

Stanford University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Stanford University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Stanford University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Stanford University, Medical Devices Deals, 2012 to YTD 2018 12

Stanford University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Stanford University, Pharmaceuticals & Healthcare, Deal Details 17

Venture Financing 17

Arcus Biosciences Raises USD70 Million in Series B Financing 17

Partnerships 19

Brainsway and Cohen Veterans Bioscience Enter into Research Collaboration Agreement with Stanford University 19

Rocket Pharmaceuticals and Stanford University School of Medicine Enter into Partnership 20

Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 21

Vibliome Therapeutics Enters into Agreement with Stanford University and Montana State University 22

Takeda Pharma Partners with Stanford University 23

Alligator Bioscience Expands Agreement with Stanford University 24

Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 25

Stanford University's School of Medicine and uBiome Enter into Research Agreement 26

Stallergenes Greer Enters into Agreement with Stanford University 27

Cohen Veterans Bioscience Enters into Agreement with Stanford University School of Medicine 28

RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 29

twoXAR Enters into Agreement with Stanford University School of Medicine 30

twoXAR Enters into Research Agreement with Stanford University 31

Intermountain Healthcare Enters into Agreement with Stanford Genome Technology Center 32

SRI Biosciences Enters into Agreement with Stanford Cancer Institute 33

ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 34

SRI Biosciences Enters into Agreement with Stanford Cancer Institute 35

aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 36

Activaero Enters Into Research Agreement With Stanford University 38

Benitec Biopharma Enters Into An Agreement With Stanford University 39

Licensing Agreements 40

Denovo Biopharma Enters into Licensing Agreement with Stanford University 40

Madenco BioSciences Enters into Licensing Agreement with Stanford University 41

Vir Biotechnology Enters into Licensing Agreement with Stanford University 42

Aldevron Enters into Licensing Agreement with Stanford University 43

Stanford University Enters into Licensing Agreement with Trianni for Trianni Mouse 44

Aduro BioTech Enters into Licensing Agreement with Stanford University 45

Neurotrope Enters into Licensing Agreement with Stanford University 46

Renova Therapeutics Enters into Licensing Agreement with Stanford University 47

Mitoconix Bio Enters into Licensing Agreement with Stanford University 48

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 49

Forty Seven Enters into Licensing Agreement with Stanford University 50

Medgenics Enters into Licensing Agreement with Stanford University 51

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 52

Eiger BioPharma Enters into Licensing Agreement with Stanford University 53

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 54

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 55

Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 56

Alexo Therapeutics Receives Rights to SIRPA technology from Stanford University School of Medicine 57

Medeor Therapeutics Enters into Licensing Agreement with Stanford University 58

CareDx Amends Licensing Agreement with Stanford University 59

Neurotrope Enters into Licensing Agreement with Stanford University 60

Horizon Discovery Enters into Licensing Agreement with Stanford University 61

Globavir Enters into Licensing Agreement with Stanford University 62

Sitari Pharma Enters into Licensing Agreement with Stanford University 63

Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 64

Personalis Enters Into Licensing Agreement With Stanford University 65

Atreca Enters Into Licensing Agreement With Stanford University For Immune Repertoire Capture Technology 66

Stem Cell Theranostics Enters into Agreement with Stanford University 67

Transparency Life Sciences Enters Into Option Licensing Agreement With Stanford University 68

Acquisition 69

Stanford Health Care Acquires ValleyCare Health 69

Stanford Hospital Acquires CareCounsel Health Advocacy Specialist 70

Stanford University-Key Competitors 71

Stanford University-Key Employees 72

Stanford University-Locations And Subsidiaries 73

Head Office 73

Other Locations & Subsidiaries 73

Recent Developments 74

Legal and Regulatory 74

Mar 05, 2018: Abzena: Settlement of claim 74

Government and Public Interest 75

Aug 08, 2018: Reaching for new stroke treatments by understanding proprioception 75

Aug 06, 2018: Correcting sickle cell-causing mutation with efficient CRISPR-Cas9 genome editing 76

Jul 30, 2018: Study links depression to low blood levels of acetyl-L-carnitine 77

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 79

Jul 18, 2018: Cell membrane's importance offers new strategy to fight infections 80

Jun 12, 2018: More than USD 28 million awarded for new atrial fibrillation research centers to improve patient outcomes 81

Jun 08, 2018: USD 8.1 million grant funds new center to research highly aggressive form of lung cancer 82

May 24, 2018: Clinical Trial Targeting Lung Cancer, Plus Promising Osteoporosis and Incontinence Research get Support from Stem Cell Agency 84

May 23, 2018: Foundation for Anesthesia Education and Research Awards USD 1.4 million in Grants 86

May 02, 2018: Cryo-EM structures of the nicotine receptor may lead to new therapies for nicotine addiction 89

Apr 03, 2018: Stanford scientists combine CRISPR and DNA barcoding to track cancer growth 90

Mar 30, 2018: Stanford researchers use computer simulations to study complexity of concussions 92

Mar 28, 2018: Revolutionary brain-mapping technique provides new blueprint for cortical connections 93

Feb 15, 2018: Breast Cancer Now responds to early research using stem cells to develop 'cancer vaccine' 94

Jan 29, 2018: Kenneth Rainin Foundation: USD 1.7 Million to Improve IBD Patient Outcomes 95

Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 96

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 99

Oct 16, 2017: Scientists uncover a new layer of Complexity Beyond the Human Genome 100

Sep 21, 2017: Pancreatic islets study may spur diabetes treatment advances 101

Sep 20, 2017: Researchers hit the brakes on lethal brain cancers in mice 102

Sep 19, 2017: CPRIT awards USD 34M to UTSW for cancer research recruitment 103

Aug 17, 2017: New Way To Empower The Immune System To Detect And Kill Cancer 105

Product News 106

Jul 17, 2017: Intermountain Healthcare and Stanford University Use Precision Medicine Advances to Understand and Treat Cancer Cases 106

May 01, 2018: Scientist develops protein mimic to help injured lungs breathe 107

Feb 15, 2018: Stem cell vaccine immunizes lab mice against multiple cancers 109

Clinical Trials 110

Nov 20, 2017: Clinical trial suggests new cell therapy for relapsed leukemia patients 110

Other Significant Developments 112

Sep 04, 2018: Tailoring behavioral therapy for depression, obesity based on how the brain responds 112

Aug 15, 2018: Healthcare Innovators professional society reaches member goal of 33 top industry executives for nationwide council 113

Aug 09, 2018: Artificial intelligence model “learns” from patient data to make cancer treatment less toxic 114

Jul 09, 2018: Synthetic surfactant could ease breathing for patients with lung disease and injury 116

Jun 26, 2018: Researchers Explore Stem Cells for Personalized Cancer Vaccines 117

Jun 07, 2018: Blood test may identify pregnant women at risk of premature birth 118

Appendix 119

Methodology 119

About GlobalData 119

Contact Us 119

Disclaimer 119


List of Figure

List of Figures

Stanford University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Stanford University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Stanford University, Medical Devices Deals, 2012 to YTD 2018 12


List of Table

List of Tables

Stanford University, Pharmaceuticals & Healthcare, Key Facts 2

Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Stanford University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Stanford University, Deals By Therapy Area, 2012 to YTD 2018 11

Stanford University, Medical Devices Deals, 2012 to YTD 2018 12

Stanford University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Arcus Biosciences Raises USD70 Million in Series B Financing 17

Brainsway and Cohen Veterans Bioscience Enter into Research Collaboration Agreement with Stanford University 19

Rocket Pharmaceuticals and Stanford University School of Medicine Enter into Partnership 20

Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 21

Vibliome Therapeutics Enters into Agreement with Stanford University and Montana State University 22

Takeda Pharma Partners with Stanford University 23

Alligator Bioscience Expands Agreement with Stanford University 24

Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 25

Stanford University's School of Medicine and uBiome Enter into Research Agreement 26

Stallergenes Greer Enters into Agreement with Stanford University 27

Cohen Veterans Bioscience Enters into Agreement with Stanford University School of Medicine 28

RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 29

twoXAR Enters into Agreement with Stanford University School of Medicine 30

twoXAR Enters into Research Agreement with Stanford University 31

Intermountain Healthcare Enters into Agreement with Stanford Genome Technology Center 32

SRI Biosciences Enters into Agreement with Stanford Cancer Institute 33

ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 34

SRI Biosciences Enters into Agreement with Stanford Cancer Institute 35

aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 36

Activaero Enters Into Research Agreement With Stanford University 38

Benitec Biopharma Enters Into An Agreement With Stanford University 39

Denovo Biopharma Enters into Licensing Agreement with Stanford University 40

Madenco BioSciences Enters into Licensing Agreement with Stanford University 41

Vir Biotechnology Enters into Licensing Agreement with Stanford University 42

Aldevron Enters into Licensing Agreement with Stanford University 43

Stanford University Enters into Licensing Agreement with Trianni for Trianni Mouse 44

Aduro BioTech Enters into Licensing Agreement with Stanford University 45

Neurotrope Enters into Licensing Agreement with Stanford University 46

Renova Therapeutics Enters into Licensing Agreement with Stanford University 47

Mitoconix Bio Enters into Licensing Agreement with Stanford University 48

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 49

Forty Seven Enters into Licensing Agreement with Stanford University 50

Medgenics Enters into Licensing Agreement with Stanford University 51

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 52

Eiger BioPharma Enters into Licensing Agreement with Stanford University 53

Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 54

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 55

Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 56

Alexo Therapeutics Receives Rights to SIRPA technology from Stanford University School of Medicine 57

Medeor Therapeutics Enters into Licensing Agreement with Stanford University 58

CareDx Amends Licensing Agreement with Stanford University 59

Neurotrope Enters into Licensing Agreement with Stanford University 60

Horizon Discovery Enters into Licensing Agreement with Stanford University 61

Globavir Enters into Licensing Agreement with Stanford University 62

Sitari Pharma Enters into Licensing Agreement with Stanford University 63

Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 64

Personalis Enters Into Licensing Agreement With Stanford University 65

Atreca Enters Into Licensing Agreement With Stanford University For Immune Repertoire Capture Technology 66

Stem Cell Theranostics Enters into Agreement with Stanford University 67

Transparency Life Sciences Enters Into Option Licensing Agreement With Stanford University 68

Stanford Health Care Acquires ValleyCare Health 69

Stanford Hospital Acquires CareCounsel Health Advocacy Specialist 70

Stanford University, Key Competitors 71

Stanford University, Key Employees 72

Stanford University, Subsidiaries 73

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022